" class="no-js "lang="en-US"> Advanced NanoTherapies - Medtech Alert
Wednesday, July 30, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Advanced NanoTherapies

Advanced NanoTherapies

About Advanced NanoTherapies

Advanced NanoTherapies

Advanced NanoTherapies, Inc. is a highly specialized medical device company developing a proprietary nanoparticle technology-based platform for drug delivery. The company focuses on minimally invasive cardiovascular applications to bring a safer therapeutic option to patients with coronary artery disease (CAD) or peripheral artery disease (PAD). The company’s first product is the SirPlux Duo DCB, a next-generation CAD and PAD front-line therapy.

Related Story

Cardiovascular

 Advanced NanoTherapies' SirPlux Duo Drug-Coated Balloon Receives FDA Breakthrough Designation for Small Vessel Coronary Artery Disease | Pharmtech Focus

Advanced NanoTherapies' SirPlux Duo Drug-Coated Balloon Receives FDA Breakthrough Designation for Small Vessel Coronary Artery Disease

September 20 2022

Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease’s most significant […]